U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Complete if Known		
Substitute for form 1449/PTO			•	Application Number	10/661,386	
INFORMATION DISCLOSURE				Filing Date	September 12, 2003	
	STATEMENT BY APPLICANT			First Named Inventor	Joseph Rubinfeld	
(Use	as many shee	ets as ne	cessary)	Art Unit	1614-1623	
				Examiner Name	Not yet assigned D. Khane	
Sheet	1	of	1	Attorney Docket Number	12636-305	

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
du		BROWN, R. et al. Demethylation of DNA by decitabine in cancer chemotherapy. Expert Rev Anticancer Ther. 2004; 4(4): 501-510.		
		GILBERT, J. et al. The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation. Clinical Cancer Research. 2004; 10: 4589-4596.		
		HERMAN, J. G. et al. Gene Silencing in Cancer in Association with Promoter Hypermethylation. The New England Journal of Medicine. 2003; 349(21): 2042-2054.		
		LEONE, G. et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. <i>Haematologica</i> . 2002; 87(12): 1324-1341.		
do		LEONE, G. et al. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin Immunol. 2003; 109(1): 89-102.		

Examiner	41110	Date	111 1104
signature	artine	Considered	130,00

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

12636-305

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO 10/661,386 **Application Number** Filing Date 09/12/2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Joseph Rubinfeld First Named Inventor 1614 1623 (Use as many sheets as necessary) Art Unit Not yet assigned **Examiner Name** D. Khee

Attorney Docket Number

	•	U.S. PA	ATENT DOC	UMENTS	
xaminer Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, When Relevant Passages or Relevant Figures Appear
ill		US-2002/0114809 A1	02/21/2001	Rubinfeld, et al.	
1		US-2002/0136709 A1	07/31/2001	Zahner, et al.	
		US-2003/0039689 A1	04/26/2002	Chen, et al.	
		US-2003/0108588 A1	09/17/2002	Chen, et al.	
		US-2003/0147813 A1	02/07/2002	Lyons	
		US-2003/0158598 A1	01/14/2003	Ashton, et al.	
		US-2003/0229047 A1	06/05/2002	Joshi-Hangal, et al.	
	-	US-2004/0019036 A1	09/05/2001	Robin, et al.	
		US-5,736,531	12/30/1993	Von Borstel, et al.	
au		US-5,968,914	10/28/1987	Von Borstel, et al.	·- ·- · · ·
					•
	·				
					<del></del>

Examiner	1.1	Date	-101
Signature	<u>allune</u>	Considered	11/30/00

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet

of

3

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

12636-305

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known **Application Number** 10/661,386 Substitute for form 1449/PTO 09/12/2003 Filing Date INFORMATION DISCLOSURE First Named Inventor Joseph Rubinfeld STATEMENT BY APPLICANT (Use as many sheets as necessary) Art Unit 1614 **Examiner Name** Not yet assigned

Attorney Docket Number

Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code' - Number' - Kind Code' (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
ge.		CS 269077	12/22/1963	Ceskoslovenska akademie ved, (Prag)		
		DE 1922702	05/03/1969	Ceskoslovenska akademie ved, (Prag)		
	•	DE 2105468	02/05/1971	Ceskoslovenska akademie ved, (Prag)		Г
		EP 286958	04/06/1988	Merck Pg		Γ
		JP 05219974	02/13/1992	Mitsui Petrochem Ind Ltd		Γ
		JP 2002223753	01/30/2001	Hitachi		Γ
		JP 2002370939	06/12/2001	Taisho Pharmaceutical Co. Ltd.		
	•	JP 2003310293	04/26/2002	Mitsui Chemical Inc.		Γ
		WO 93/01202	07/05/1991	Pro-Neuron, Inc.		Γ
-71		WO 94/26761	05/14/1993	Pro-Neuron, Inc.		Γ
7		WO 94/27632	06/01/1993	Nycomed Pharma A/S		Γ
		WO 96/40165	06/07/1995	Pro-Neuron, Inc.		Γ
		WO 99/01118	07/01/1997	Artherogenics, Inc.		Γ
		WO 00/23112	10/19/1998	Methylgene, Inc.	,	Γ
		WO 00/40269	01/05/1999	Clarence Lee		Γ
		WO 00/74634 A2	06/03/1999	AU, Jessie, L., S.		Γ
	•	WO 01/79164 A2	03/21/2000	Atherogenics, Inc.		Γ
		WO 02/47611 A2	11/28/2000	Board of Regents of the University of Texas System		
pl		WO 02/053138 A2	01/02/2001	Shanahan-Prendergast, Elisabeth		Γ

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet

of

2

3

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known **Application Number** 10/661,386 Substitute for form 1449/PTO 09/12/2003 Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Joseph Rubinfeld (Use as many sheets as necessary) Art Unit 1614 Examiner Name Not yet assigned 12636-305 of 3 Attorney Docket Number Sheet 3

		FOREIGN	PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>3</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
all		WO 02/057425 A2	01/22/2001	Merck & Co., Inc.		Τ.
		WO 02/076486 A2	02/05/2001	Innoventus Project AB		Γ
		WO 02/085400 A1	04/24/2001	Supergen, Inc.		Γ
		WO 03/020252 A2	09/05/2001	Oncopharm Corporation		Γ
		WO 03/026574 A2	09/24/2001	AU, Jessie, LS.		Γ
		WO 03/046190 A1	11/30/2001	Medigene ·Aktiengesellschaft		
		WO 03/065995 A2	02/07/2002	SuperGen, Inc.		Γ
		WO 03/076593 A2	03/07/2002	The Johns Hopkins University School of Medicine		
		WO 03/076594 A2	03/07/2002	The Johns Hopkins University		
		WO 2003/087774 A3	04/12/2002	Curators of the University of Missouri		
		WO 03/092623 A2	05/02/2002	Wyeth Holdings Corporation		
M		WO 2004/009023 A2	07/18/2002	University of Utah Research Foundation		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to fake 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

· · · · · · · · · · · · · · · · · · ·			•	Сон	Complete if Known		
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/661,386		
			LOSURE	Filing Date	September 12, 2003		
				First Named Inventor	Joseph Rubinfeld		
(Use a	s many shee	is as ne	cessary)	Art Unit	1614 1623		
				Examiner Name	Not yet Assigned D. Khore		
Sheet	1	of	. 1	Attorney Docket Number	12636-305		

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
R\		US-4,690,918	09/01/87	Ebppu, et al.	•	
		US-			•	
		US-			•	
		US-			•	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Cods' - Number' - Klod Cods' (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appent	T*			
dh		PCT/US04/22367 International Search Report	07/20/05	Supergen, Inc.					
	•				1				

Examiner Cit Initials* No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title o item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue numbe publisher, city and/or country where published.					
an		Von Hoff, et al.; "A New Anticancer Drug with Effectiveness in Acute Myelogenous Leukemia"; 5-Azacytidine, Annals of Internal Medicine, 1976, 85, vol. 2, pages 237-245					

Examiner Signature	ollhane	. Date Considered	1/30/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at wew.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Sandard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the spropriate symbols as indicated on the document wider WIPO Sandard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

Transition is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patenta, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

2711872\_1.DOC Attorney Docket No. [Docket #] 08A (10-01)



Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. Department of Commerce

Juder the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known 10/661,386 Substitute for form 1449A/PTO Application No. 09/12/2003 INFORMATION DISCLOSURE Filing Date Rubinfeld STATEMENT BY APPLICANT First Named Inventor Not yet assigned | 623 (Use as many sheets as necessary) **Art Unit** Not-yet assigned D. Khar Examiner Name 12636.305 Attorney Docket No. 2 Of Sheet

	U.S. PATENT DOCUMENTS					
		Document No.		·		
Examiner's Initials	Cite No.	Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
<del></del>		US-			<u> </u>	
<del></del>		US-				
	1	US-				
	1	US-			<u></u>	

		FOREIGN	PATENT DO	CUMENTS	· · · · · · · · · · · · · · · · · · ·
		Foreign Patent Document			
Examiner's Initials	Cite No.1	Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cohimns, Lines, Where Relevant Passages or Relevant Figures Appear
JL.		WO 02/069903	09/12/2002	Biocryst Pharmaceuticals, Inc.	
			·		
		·			
				<u> </u>	
EXAMINER		deline	<u></u>	DATE CONSIDERED	130106

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

experience: Initial in reference considered, whether or not cliented is in contaminate with tyre of the initial in the initial interest in the experiment of the applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPBP 901.04. 3 Enter Office that 1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents, the indication of the year of the reign of the Emperor must precede issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

		-61005 por	ersoms required t	o respond to a collection of information unless	PTC/SB/08A (10-01 Approved for use through 10/31/2002. OMB 0651-003 atent and Trademark Office: U.S. Department of Commerce s it contains a valid OMB control number.	
er the paperwork	Reduction Ac	1 01 1995, 100		Com	plete if Known	
Substitute fo	Substitute for form 1449A/PTO			Application No.	10/661,386	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			OSURE	Filing Date	09/12/2003 Rubinfeld	
			ICANT	First Named Inventor		
			ary)	Art Unit	Not yet assigned	
				Examiner Name	Not yet assigned	
	1 - 1		1 2	Attorney Docket No.	12636.305	
Sheet	2	Of	1			

		OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS  Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T <sup>2</sup>
aminer itials*	Cite No.1	Item (book, magazine, journal, serial, symptoment)  number(s) publisher city and/or country where published	
ale		SHEIKHNEJAD, G. et al., "Mechanism of inhibition of DNA (cytosine C5)-	
		methyltransferases by oligodeoxyribonucleouties containing 3,5-umyuro 5	
11			
		GOFFIN I et al. "DNA methyltransferase innibitors—state of the art, 70 mais by	
- 1 1			
pr			l
·		for the treatment of high-risk myelodyspiastic syndrome. a municetta patterns of high-risk myelodyspiastic syndrome. a municetta patterns of clinical Oncology, March 2000, pages 956-962, Vol. 18, No. 5	
			<b>↓</b>
	1		┼╌
			_
	ļ		$\top$
			+-
	<u> </u>		
	+		
		·	+
•			+-
	+-		
	+-		
EXAM	INTER	DATE CONSIDERED AN 30 06	

<sup>\*</sup>BXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.